Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Anti-Infective Agents" patented technology

Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.

1h-pyrazolo[3,4-d]pyrimidin-4-amines as Anti-infectious agents

PCT designated stage expiredWO2024249380A2Organic chemistryCryptosporidium infectionMedicine
Owner:UNIVERSITY OF VERMONT +1

Homeopathic complex

The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and / or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius solubilis or similar mercury containing remedy and Silica or other silica containing compounds.
Owner:FARRINGTON DANIEL +1

Apparatus, systems, and methods for determining the concentration of microorganisms and the susceptibility of microorganisms to anti-infectives based on redox reactions

Various methods, devices, and systems for determining the concentration of microorganisms in a sample and determining the susceptibility of such microorganisms to one or more antibiotics or other types of anti-infectives are disclosed herein. More specifically, methods for quantifying microorganisms based on redox reactions are disclosed along with systems and devices for quantifying such microorganisms using certain oxidation reduction potential (ORP) sensors. Moreover, methods for determining the susceptibility and the degree of susceptibility of microorganisms to one or more anti-infectives are disclosed along with multiplex systems for such assays.
Owner:AVAILS MEDICAL INC

Biocompatible composite material and method of making the same

Disclosed herein is biocompatible composite material impregnated with antiinfective agents to reduce the rate of infection in patients with medical implants. Also disclosed herein is the utilization of super critical fluid (SCF) methodology to impregnate medical implant materials with antiinfective agents (e.g., antimicrobial, antibiofilm agents, etc.).
Owner:SANVIA LLC

Compositions, uses and methods for attenuating anti-infective resistance

A composition is disclosed that includes a chelating polymer including a first monomer unit and a second monomer unit polymerized by a reversible addition-fragmentation chain transfer mechanism using an addition-fragmentation chain transfer agent, and an anti-infective agent. The composition can be used to treat a bacterial infection or to reduce bacterial resistance to the anti-infective agent in a subject.
Owner:FE PHARM (CANADA) INC

Apparatus, systems, and methods for determining the susceptibility of infectious agents to Anti-infectives

Various methods, devices, and systems for determining the susceptibility of infectious agents to anti-infectives are disclosed herein. A method comprises introducing an inoculum solution comprising the infectious agent into a sample receiving space of a diagnostic device. The sample receiving space comprises a plurality of growth control wells devoid of the anti-infective and a plurality of active electrode wells comprising the anti-infective at differing concentrations. A water immiscible liquid can be introduced into the sample receiving space to seal the plurality of wells and the diagnostic device can be incubated for a period of time. The minimum inhibitory concentration (MIC) of the anti-infective on the infectious agent can be determined by monitoring and comparing one or more solution characteristics of the inoculum solution within the active electrode wells with the one or more solution characteristics of the inoculum solution with the growth control wells.
Owner:AVAILS MEDICAL INC

Covalent inhibitors as Anti-malarial agents

The present application generally relates to compounds, pharmaceutical compositions and method to treat a patient with malaria related disease or Plasmodium infection. Particularly the method compromises the step of administering a therapeutically effective amount of the disclosed compounds or compositions, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.
Owner:PURDUE RES FOUND +1

Targeted dynamic antimicrobial systems

The invention relates to a molecular system comprising: (i) at least one dynamic constitutional framework (DCF) comprising a plurality of cores and a plurality of connectors, (ii) a plurality of functional heads, (iii) at least one pillararene and, optionally, (iv) at least one anti-infective agent; wherein each of the anti-infective agents is hosted in one of the pillararenes; wherein the cores, connectors, functional heads, and pillararenes are covalently bound together by reversible bonds; and wherein each of the cores is covalently bound to at least three from the connectors, functional heads and pillararenes. The invention also relates to a pharmaceutical composition or medicament comprising the molecular system. The invention also relates to the molecular system for use in the treatment of an infectious disease such as a bacterial disease, preferably a disease caused by Acinetobacter baumannii bacteria.
Owner:UNIV DE NAMUR +3

Functionalized imidazopyrimidine compounds and uses thereof

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. The compound of Formula (I) is used as an enhancer and / or modifier of an immune response (e.g., innate and / or adaptive immune response), and is useful in treating and / or preventing a disease, as an adjuvant in a vaccine for a disease, (e.g., a proliferative disease, an inflammatory disease, an autoimmune disease, an infectious disease, an allergy, a fibrotic disease, a cardiovascular disease, a graft rejection, graft-versus-host disease, chronic disease, addiction, or risk of drug overdose), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are vaccines, pharmaceutical compositions, kits, methods, and uses including or using compounds of Formula (I).
Owner:CHILDRENS MEDICAL CENT CORP +1

Methods of clearing mucus from the lungs

Provided herein are compositions and methods for clearing mucus (e.g., excess mucus) from the lungs. In one aspect, provided herein are methods of clearing mucus from the lungs of a subject in need thereof comprising instilling into the lungs of the subject an effective amount of a liquid pharmaceutical composition comprising an isotonic osmolyte. The liquid pharmaceutical composition (e.g., aqueous, isotonic sodium gluconate solution) may further comprise one or more additional agents selected from epithelial sodium channel (ENaC) inhibitors, osmolytes mucolytic agents, surfactants, DNases, anti-infectives, and anti-inflammatory agents. Also provided herein are liquid pharmaceutical compositions (i.e., "instillation solutions," "lavage solutions") useful in the methods described herein.
Owner:PARION SCIENCES INC

Tools to target natural and synthetic nucleotide-sensing pathways

PendingUS20260034157A1Organic active ingredientsAntiinfectivesSynthetic nucleotideNucleotidase
The present invention provides for compositions and methods for deploying ddhNTPs as immunomodulatory therapeutics to modulate P2 receptors, as nucleotidase inhibitors, for applications like host-acting anti-infectives, oncolytics, anti-aging agents, or tissue regeneration agents.
Owner:RGT UNIV OF CALIFORNIA